Totally implantable venous catheter in 278 oncology patients

• Autor(a) principal: Brandão , Miguel Ângelo
• Data de Publicação: 2023
• Outros Autores: Rodrigues , Zildo, Sampaio, Sandra, Acioli, Joberto, Sampaio, Carlos
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista Brasileira de Cancerologia (Online)
• Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/3401
• topic: Cateter Totalmente Implantável; Câncer; Acesso Venoso Longa Permanência; Catéter; Long-Term Venous Access; Cateter; Indwelling; Vascular Access; Cancer

Totally implanted venous catheter provides safe and comfortable long-term vascular access. Implantation and removal of the catheter is associated with low risk of complication. Our objetive is to report the experience ivith 278 ports implanted by a single surgeon in our institution. To be selected for the procedure patients needed: histological proven cancer, estimated survival of more than 3 months and indication of systemic chemoterapy. Surgical and maintenance protocols were previously defined. Between 3190 and 3/98, 278 catheters ivere im planted in 272 patients. The study average follow-up is 382 days (5-2897), with a total of 106.457 days. Mean age ofthe patients was 50,2 years and female patients comprised 64,8% of the population. Access vein were: internaijugular (67,9%), external jugular (26,5%), saphena (2,2%>), cephlic (1,7%) and subclavia (1,7%). The most commom complication was reversible obstruction (0,2611000 days); hematoma (6,11% of the total population and 62% of the in leukemic patients), leaking (0,2/1000 days); thombosis (0,03/1000 days); occurred less frequently. Twenty episodies of infection were reported 0,19/1000 days: lumen (6), peri-porth (7) and sepsis (7). Thirty-four ports were removed, 26 due to complications and 8 at the end ofthe treatment. Currently, 45,2% of the patients are alive with functional catheters. Among all patients, 74,5% had no catheter-related complication. In our experience, catheters represent a safe and efficient adjuvant in cancer patients. Leukemic patients are at high risk for complications, mainly hematomas.